RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Someone Needs To Read The Balance SheetEverything management does has to be in the context of the sole purpose of maximizing shareholder value, which in a public market manifests itself into higher share prices. The question is whether that is achieved by being some market leader in a market that may be small i.e. think eps. Increasing the operating profit with the bioreactor is fine, but there has to be more exciting revenue growth as well. And right now we have to survive at least a year to benefit from those operating efficiencies. Overall, it is not clear that they have the means to service the debt they acquired, either for this particular business line or the other initiatives. In other words, has management made prudent decisions over time weighing the risk and rewards. The market is saying no. I don't know what is going on with different negotiations, but I would say that time is of the essence and if they have a good deal (profitable, cashflow positive operations) in front of them, they may be better to take the good deal now and get on with it rather than to take the risk and fight for the best deal. If you are down 3 runs in the 9th inning, maybe try getting back into the game by hitting some singles and doubles and maybe one home run to bring some runners in than trying for 3 home runs when you don't have the sluggers that can do that with any meaningful odds. Confidence needs to be restored and pronto.